Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0181 in Advanced Hepatocellular Carcinoma
NCT04973098Phase 1Unknown
- Sponsor
- Peking University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0181 in hepatocellular carcinoma (HCC), sponsored by Peking University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximal Tolerable Dose at 28 days and 2 more. Status: unknown.
02
Drugs
CT0181
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04973098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973098.